Cyclacel Pharmaceuticals Inc (CYCC)
0.39
-0.06
(-14.29%)
USD |
NASDAQ |
Nov 14, 16:00
0.382
-0.01
(-2.05%)
After-Hours: 20:00
Cyclacel Pharmaceuticals Enterprise Value: -5.102M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | -5.102M |
| November 12, 2024 | -5.191M |
| November 11, 2024 | -5.114M |
| November 08, 2024 | -5.050M |
| November 07, 2024 | -5.160M |
| November 06, 2024 | -5.180M |
| November 05, 2024 | -5.127M |
| November 04, 2024 | -5.003M |
| November 01, 2024 | -4.762M |
| October 31, 2024 | -4.719M |
| October 30, 2024 | -4.703M |
| October 29, 2024 | -4.657M |
| October 28, 2024 | -4.618M |
| October 25, 2024 | -4.358M |
| October 24, 2024 | -4.281M |
| October 23, 2024 | -3.907M |
| October 22, 2024 | -3.177M |
| October 21, 2024 | -3.394M |
| October 18, 2024 | -3.749M |
| October 17, 2024 | -4.006M |
| October 16, 2024 | -4.046M |
| October 15, 2024 | -4.394M |
| October 14, 2024 | -4.421M |
| October 11, 2024 | -4.421M |
| October 10, 2024 | -4.430M |
| Date | Value |
|---|---|
| October 09, 2024 | -4.415M |
| October 08, 2024 | -4.243M |
| October 07, 2024 | -4.144M |
| October 04, 2024 | -4.197M |
| October 03, 2024 | -4.184M |
| October 02, 2024 | -4.164M |
| October 01, 2024 | -4.124M |
| September 30, 2024 | -4.046M |
| September 27, 2024 | -3.967M |
| September 26, 2024 | -4.026M |
| September 25, 2024 | -3.986M |
| September 24, 2024 | -3.967M |
| September 23, 2024 | -4.046M |
| September 20, 2024 | -4.065M |
| September 19, 2024 | -3.986M |
| September 18, 2024 | -3.937M |
| September 17, 2024 | -3.986M |
| September 16, 2024 | -3.967M |
| September 13, 2024 | -4.006M |
| September 12, 2024 | -3.907M |
| September 11, 2024 | -3.848M |
| September 10, 2024 | -3.907M |
| September 09, 2024 | -3.828M |
| September 06, 2024 | -3.907M |
| September 05, 2024 | -3.927M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-18.55M
Minimum
Jun 13 2022
43.63M
Maximum
Mar 19 2021
-0.8349M
Average
-2.913M
Median
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 3.432M |
| Palatin Technologies Inc | 13.74M |
| iBio Inc | 6.814M |
| Theriva Biologics Inc | -13.26M |
| Oragenics Inc | 2.142M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.257M |
| Revenue (Quarterly) | 0.004M |
| Total Expenses (Quarterly) | 3.648M |
| EPS Diluted (Quarterly) | -0.72 |
| Profit Margin (Quarterly) | -81.42K% |
| Earnings Yield | -4.21K% |
| Normalized Earnings Yield | -4144.04 |